Inhibrix Pulls In $40M to Press Ahead With Cancer Drug Clinical Trials

Inhibrx, developer of protein drugs targeting cancer and other diseases, has raised $40 million from the hedge fund Viking Global Investors as the biotech steers several programs through early-stage clinical trials. The La Jolla, CA-based company was founded in 2010 by Mark Lappe, Brendan Eckelman, and Quinn Deveraux. Eckelman is the company?s chief scientific officer [?]